TP53 and anaplastic large cell lymphoma: Consistent with this, a recent cohort study in 82 ALCL patients with systemic ALCL (ALK+ and ALK-) identified that mutations in TP53 and STAT3 are associated with a worse prognosis independent of ALK status (49).